RIPE-KG · Version 1.1.0 · Resource

ripekg:registry-evidence/RIPEA10E0E50BEC9CF233

https://w3id.org/ripe/ripe-kg/registry-evidence/RIPEA10E0E50BEC9CF233

Subject	Predicate	Object
`ripekg:evaluation/RIPEA10E0E50BEC9CF233`	`prov:used`	`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`rdf:type`	`rdfs:Resource`
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`rdf:type`	`owl:Thing`
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`rdf:type`	`ripe:IntegrityAssessmentEvidence`Integrity assessment evidence
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`rdf:type`	`ripe:RegistryEvidence`Registry evidence
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`rdf:type`	`tido:Evidence`
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`prov:wasAttributedTo`	`ripekg:source/clinicaltrials-gov`ClinicalTrials.gov
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`prov:wasGeneratedBy`	`ripekg:evidence-aggregation/RIPEA10E0E50BEC9CF233`
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`prov:wasMemberOf`	`ripekg:research-integrity-assessment/RIPEA10E0E50BEC9CF233`
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:concerns`	`ripekg:work/10.1136%2Fbmj-2025-084290`Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:concerns`	`ripekg:work/10.1136%2Fbmj-2025-084290`Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:isProspective`	true
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:registrationAssessmentRationale`	Comparison performed at month level. Registration: 2021-12, LLM Recruitment Start: 2022-01. Deemed prospective at month level.
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:registrationDate`	20-12-2021
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:registrationId`	NCT05165069
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:registrationLink`	https://clinicaltrials.gov/study/NCT05165069
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`ripe:registryName`	ClinicalTrials.gov
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEA10E0E50BEC9CF233-human-2-2`
`ripekg:registry-evidence/RIPEA10E0E50BEC9CF233`	`tido:supports`	`ripekg:integrity-assessment-hypothesis/RIPEA10E0E50BEC9CF233-inspectai-2-2`